• Actuate Therapeutics published a post-hoc efficacy and biomarker analysis from its phase 2 1801 Part 3B study in first-line metastatic pancreatic cancer.
• Landmark analysis in patients completing at least one cycle showed median overall survival of 12.5 months with elraglusib plus chemotherapy vs 8.5 months with chemotherapy alone.
• Subgroup results showed longer survival signals in patients with baseline albumin ≥3 g/dL or CA19-9 <8,000 U/mL on the elraglusib regimen.
• Exploratory biomarker work linked KRAS, TP53, CDKN2A, or SMAD4 alterations to worse survival only in the elraglusib arm.
• Outcomes appeared stronger in Europe than North America, with early mortality of 5.3% vs 15.4% in the elraglusib arm.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.